Morgan Stanley’s InMed Pharmaceuticals INM Stock Holding History

Morgan Stanley’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Hold	0	–	-$2	–	7772
2022 Q4	–	Sell	-7	Closed	-$471	–	7857
2022 Q3	$1K	Buy	+7	New	+$1.3K	﹤0.01%	7568
2022 Q2	–	Hold	0	–	–	–	7886
2021 Q4	–	Hold	0	–	–	–	8031
2021 Q3	–	Sell	-2	Closed	-$2.38K	–	7973
2021 Q2	$2K	Sell	2 -23	-92%	-$35.6K	﹤0.01%	7525
2021 Q1	$41K	Buy	25 +11	+79%	+$23.6K	﹤0.01%	6436
2020 Q4	$23K	Buy	+14	New	+$22.7K	﹤0.01%	6392

Other funds holding INM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Morgan Stanley's INM Position: Q1 2023 in Review

Morgan Stanley held its InMed Pharmaceuticals (INM) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7772.

Morgan Stanley first reported a position in INM in Q4 2020 and has held it in 4 quarters since. The position peaked at $41K in Q1 2021. 11 funds tracked by Wall St. Rank hold INM as of Q1 2023.

Morgan Stanley held 0 shares of InMed Pharmaceuticals worth $0 as of Q1 2023.
Morgan Stanley left its InMed Pharmaceuticals share count unchanged in Q1 2023.
InMed Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2023, its #7772 holding.
Morgan Stanley first reported a position in InMed Pharmaceuticals in Q4 2020 and has held it in 4 quarters since.
Morgan Stanley's InMed Pharmaceuticals position peaked at $41K in Q1 2021.
11 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.